Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis

Several reports suggest that gemcitabine (GEM) plus S-1 combination (GS) is associated to prolong the survival in patients with unresectable pancreatic cancer (PC). We conducted a systemic review and meta-analysis of studies comparing the safety and efficacy of GS versus GEM. Summary data from rando...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Doudou, Chen, Changhao, Zhou, Yu, Chen, Rufu, Fan, Xinxiang, Bi, Zhuofei, Li, Zhihua, Liu, Yimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616522/
https://www.ncbi.nlm.nih.gov/pubmed/26334891
http://dx.doi.org/10.1097/MD.0000000000001345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616522/
https://www.ncbi.nlm.nih.gov/pubmed/26334891
http://dx.doi.org/10.1097/MD.0000000000001345

Ejemplares similares